Multiple sclerosis - Established and novel therapeutic approaches

Central Nervous System Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 3-15

  Ehling, Rainer ^a   Berger, Thomas ^a   Reindl, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Immunomodulation; Immunosuppression; Inflammation; Monoclonal antibodies; Multiple sclerosis; Neurodegeneration; Neuroprotection

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; BHT 3009; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DNA VACCINE; ERYTHROPOIETIN; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; LAMOTRIGINE; LAQUINIMOD; MATRIX METALLOPROTEINASE; METHOTREXATE; MINOCYCLINE; MITOXANTRONE; MYELIN BASIC PROTEIN[82-98]; NATALIZUMAB; PLACEBO; RITUXIMAB; TEMSIROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; MENSTRUATION DISORDER; MONOTHERAPY; MOUTH ULCER; MULTIPLE SCLEROSIS; NERVE FIBER; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMYELINIZATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

EID: 77951110217     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152410790780127     Document Type: Review

References (149)

1. Lublin, F.D.; Reingold, S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 1996, 46, 907-911.
2. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2002, 359, 1221-1231.
3. Filippi, M.; Horsfield, M.A.; Morrissey, S.P.; Macmanus, D.G.; Rudge, P.; Mcdonald, W.I.; Miller, D.H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology, 1994, 44, 635-641.
4. Stone, L.A.; Smith, M.E.; Albert, P.S.; Bash, C.N.; Maloni, H.; Frank, J.A.; Mcfarland, H. F. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology, 1995, 45, 1122-1126.
5. Mckenzie, B.S.; Kastelein, R.A.; Cua, D.J. Understanding the IL- 23-IL-17 immune pathway. Trends Immunol., 2006, 27, 17-23.
6. Iwakura, Y.; Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest., 2006, 116, 1218-1222.
7. Babbe, H.; Roers, A.; Waisman, A.; Lassmann, H.; Goebels, N.; Hohlfeld, R.; Friese, M.; Schroder, R.; Deckert, M.; Schmidt, S.; Ravid, R.; Rajewsky, K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med., 2000, 192, 393-404.
8. Jacobsen, M.; Cepok, S.; Quak, E.; Happel, M.; Gaber, R.; Ziegler, A.; Schock, S.; Oertel, W.H.; Sommer, N.; Hemmer, B. Oligo-clonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain, 2002, 125, 538-550. (Pubitemid 34194409)
9. Neumann, H.; Medana, I.M.; Bauer, J.; Lassmann, H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci., 2002, 25, 313-319. (Pubitemid 34667013)
10. Kohm, A.P.; Carpentier, P.A.; Anger, H.A.; Miller, S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol., 2002, 169, 4712-4716.
11. Von Boehmer, H. Mechanisms of suppression by suppressor T cells. Nat. Immunol., 2005, 6, 338-344. (Pubitemid 41716770)
12. Korn, T.; Reddy, J.; Gao, W.; Bettelli, E.; Awasthi, A.; Petersen, T.R.; Backstrom, B.T.; Sobel, R.A.; Wucherpfennig, K.W.; Strom, T.B.; Oukka, M.; Kuchroo, V.K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med., 2007, 13, 423-431.
13. Rock, K.L.; Benacerraf, B.; Abbas, A.K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med., 1984, 160, 1102-1113.
14. Mcfarland, H.F. The B cell-old player, new position on the team. N. Engl. J. Med., 2008, 358, 664-665.
15. Lucchinetti, C.; Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol., 2000, 47, 707-717. (Pubitemid 30390191)
16. Medana, I.; Martinic, M.A.; Wekerle, H.; Neumann, H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol., 2001, 159, 809-815. (Pubitemid 32847171)
17. Bitsch, A.; Schuchardt, J.; Bunkowski, S.; Kuhlmann, T.; Bruck, W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain, 2000, 123, 1174-1183. (Pubitemid 30312109)
18. Nicot, A.; Ratnakar, P.V.; Ron, Y.; Chen, C.C.; Elkabes, S. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain, 2003, 126, 398-412. (Pubitemid 36172744)
19. Pitt, D.; Werner, P.; Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med., 2000, 6, 67-70. (Pubitemid 30048528)
20. Kornek, B.; Storch, M.K.; Bauer, J.; Djamshidian, A.; Weissert, R.; Wallstroem, E.; Stefferl, A.; Zimprich, F.; Olsson, T.; Linington, C.; Schmidbauer, M.; Lassmann, H. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain, 2001, 124, 1114-1124. (Pubitemid 32510379)
21. Bruck, W.; Schmied, M.; Suchanek, G.; Bruck, Y.; Breitschopf, H.; Poser, S.; Piddlesden, S.; Lassmann, H. Oligodendrocytes in the early course of multiple sclerosis. Ann. Neurol., 1994, 35, 65-73. (Pubitemid 24027608)
22. Prineas, J.W.; Barnard, R.O.; Kwon, E.E.; Sharer, L.R.; Cho, E.S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol., 1993, 33, 137-151. (Pubitemid 23039922)
23. Prineas, J.W.; Barnard, R.O.; Revesz, T.; Kwon, E.E.; Sharer, L.; Cho, E.S. Multiple sclerosis. Pathology of recurrent lesions. Brain, 1993, 116 ( Pt 3), 681-693.
24. Miller, D.H.; Albert, P.S.; Barkhof, F.; Francis, G.; Frank, J.A.; Hodgkinson, S.; Lublin, F. D.; Paty, D.W.; Reingold, S.C.; Simon, J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol., 1996, 39, 6-16.
25. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983, 33, 1444-1452.
26. Compston, A.; Confavreux, C.; Lassmann, H.; Mcdonald, I.; Miller, D.H.; Noseworthy, J.; Smith, K.; Weckerle, H. McAlpine's Multiple Sclerosis; Churchill Livingston Elsevier: Philadelphia, 2005.
27. Beck, R.W.; Cleary, P.A.; Trobe, J.D.; Kaufman, D.I.; Kupersmith, M.J.; Paty, D.W.; Brown, C.H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N. Engl. J. Med., 1993, 329, 1764-1769.
28. Hauser, S.L.; Dawson, D.M.; Lehrich, J.R.; Beal, M.F.; Kevy, S.V.; Propper, R.D.; Mills, J. A.; Weiner, H.L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med., 1983, 308, 173-180.
29. Hartung, H.P.; Gonsette, R.; Konig, N.; Kwiecinski, H.; Guseo, A.; Morrissey, S.P.; Krapf, H.; Zwingers, T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 2002, 360, 2018-2025.
30. Krapf, H.; Morrissey, S.P.; Zenker, O.; Zwingers, T.; Gonsette, R.; Hartung, H.P. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology, 2005, 65, 690-695.
31. Brunmark, C.; Runstrom, A.; Ohlsson, L.; Sparre, B.; Brodin, T.; Astrom, M.; Hedlund, G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 130, 163-172. (Pubitemid 35240003)
32. Yang, J.S.; Xu, L.Y.; Xiao, B.G.; Hedlund, G.; Link, H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol., 2004, 156, 3-9.
33. Polman, C.; Barkhof, F.; Sandberg-Wollheim, M.; Linde, A.; Nordle, O.; Nederman, T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology, 2005, 64, 987-991. (Pubitemid 40388448)
34. Comi, G.; Abramsky, O.; Arbizu, T.; Boiko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, K.; Sharrack, B.; Filippi, M. The effect of two doses of Laquinimod on MRI-monitored disease activity in patients with relapsing-remitting Multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study. Neurology 2007, 68(Suppl 1), A84.
35. Sipe, J.C.; Romine, J.S.; Koziol, J.A.; Mcmillan, R.; Zyroff, J.; Beutler, E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 1994, 344, 9-13. (Pubitemid 24199417)
36. Romine, J.S.; Sipe, J.C.; Koziol, J.A.; Zyroff, J.; Beutler, E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians, 1999, 111, 35-44. (Pubitemid 29047108)
37. Rice, G.P.; Filippi, M.; Comi, G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology, 2000, 54, 1145-1155.
38. Korn, T.; Toyka, K.; Hartung, H.P.; Jung, S. Suppression of experimental autoimmune neuritis by leflunomide. Brain, 2001, 124, 1791-1802. (Pubitemid 32845440)
39. O'Connor, P.W.; Li, D.; Freedman, M.S.; Bar-or, A.; Rice, G.P.; Confavreux, C.; Paty, D. W.; Stewart, J.A.; Scheyer, R. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology, 2006, 66, 894-900. (Pubitemid 43739766)
40. Kappos, L.; Barkhof, F.; Desmet, A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J. Neurol., 2007, 252(Suppl 2), 46.
41. Martino, G.; Pluchino, S. The therapeutic potential of neural stem cells. Nat. Rev. Neurosci., 2006, 7, 395-406.
42. Lassmann, H. Stem cell and progenitor cell transplantation in multiple sclerosis: the discrepancy between neurobiological attraction and clinical feasibility. J. Neurol. Sci., 2005, 233, 83-86. (Pubitemid 40804820)
43. Muraro, P. A.; Bielekova, B. Emerging therapies for multiple sclerosis. Neurotherapeutics, 2007, 4, 676-692.
44. Burt, R.K.; Cohen, B.A.; Russell, E.; Spero, K.; Joshi, A.; Oyama, Y.; Karpus, W.J.; Luo, K.; Jovanovic, B.; Traynor, A.; Karlin, K.; Stefoski, D.; Burns, W.H. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation- based conditioning regimen to prevent disease progression in patients with high disability scores. Blood, 2003, 102, 2373-2378.
45. Fassas, A.; Anagnostopoulos, A.; Kazis, A.; Kapinas, K.; Sakellari, I.; Kimiskidis, V.; Smias, C.; Eleftheriadis, N.; Tsimourtou, V. Autologous stem cell transplantation in progressive multiple sclerosis- an interim analysis of efficacy. J. Clin. Immunol., 2000, 20, 24-30. (Pubitemid 30210103)
46. Nash, R.A.; Bowen, J.D.; Mcsweeney, P.A.; Pavletic, S.Z.; Maravilla, K.R.; Park, M.S.; Storek, J.; Sullivan, K.M.; Al-Omaishi, J.; Corboy, J.R.; Dipersio, J.; Georges, G.E.; Gooley, T.A.; Holmberg, L.A.; Lemaistre, C.F.; Ryan, K.; Openshaw, H.; Sunderhaus, J.; Storb, R.; Zunt, J.; Kraft, G. H. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood, 2003, 102, 2364-2372.
47. Ni, X.S.; Ouyang, J.; Zhu, W.H.; Wang, C.; Chen, B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three year of follow up in 21 patients. Clin. Transplant., 2006, 20, 485-489. (Pubitemid 43983828)
48. Saccardi, R.; Mancardi, G.L.; Solari, A.; Bosi, A.; Bruzzi, P.; Di Bartolomeo, P.; Donelli, A.; Filippi, M.; Guerrasio, A.; Gualandi, F.; La Nasa, G.; Murialdo, A.;. Pagliai, F.; Papineschi, F.; Scappini, B.; Marmont, A. M. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood, 2005, 105, 2601-2607.
49. Saiz, A.; Blanco, Y.; Carreras, E.; Berenguer, J.; Rovira, M.; Pujol, T.; Marin, P.; Arbizu, T.; Graus, F. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology, 2004, 62, 282-284. (Pubitemid 38167140)
50. Inglese, M.; Mancardi, G. L.; Pagani, E.; Rocca, M. A.; Murialdo, A.; Saccardi, R.; Comi, G.; Filippi, M. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 643-644. (Pubitemid 38406670)
51. Metz, I.; Lucchinetti, C.F.; Openshaw, H.; Garcia-Merino, A.; Lassmann, H.; Freedman, M. S.; Atkins, H.L.; Azzarelli, B.; Kolar, O.J.; Bruck, W. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain, 2007, 130, 1254-1262. (Pubitemid 47355940)
52. Panitch, H.S.; Hirsch, R.L.; Haley, A.S.; Johnson, K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1987, 1, 893-895.
53. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology, 1993, 43, 655-661.
54. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology, 1995, 45, 1277-1285.
55. Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H.; Alam, J.J.; Bartoszak, D.M.; Bourdette, D.N.; Braiman, J.; Brownscheidle, C.M.; Coats, M.E.; Cohan, S.L.; Dougherty, D.S.; Kinkel, R.P.; Mass, M.K.; Munschauer, F.E., 3rd; Priore, R.L.; Pullicino, P.M.; Scherokman, B.J.; Whitham, R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol., 1996, 39, 285-294.
56. Ebers, G.C.; PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 1998, 352, 1498-1504.
57. Jacobs, L.D.; Beck, R.W.; Simon, J.H.; Kinkel, R.P.; Brownscheidle, C.M.; Murray, T.J.; Simonian, N.A.; Slasor, P.J.; Sandrock, A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med., 2000, 343, 898-904.
58. Kappos, L.; Freedman, M.S.; Polman, C.H.; Edan, G.; Hartung, H.P.; Miller, D.H.; Montalban, X.; Barkhof, F.; Radu, E.W.; Bauer, L.; Dahms, S.; Lanius, V.; Pohl, C.; Sandbrink, R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, 2007, 370, 389-397.
59. Kappos, L.; European Study Group on interferon beta-1β in secondary progressive MS.Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet, 1998, 352, 1491-1497.
60. Panitch, H.; Miller, A.; Paty, D.; Weinshenker, B. Interferon beta- 1b in secondary progressive MS: results from a 3-year controlled study. Neurology, 2004, 63, 1788-1795.
61. Kappos, L.; Weinshenker, B.; Pozzilli, C.; Thompson, A.J.; Dahlke, F.; Beckmann, K.; Polman, C.; Mcfarland, H. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology, 2004, 63, 1779-1787. (Pubitemid 39532369)
62. Hartung, H.P.; Polman, C.; Bertolotto, A.; Deisenhammer, F.; Giovannoni, G.; Havrdova, E.; Hemmer, B.; Hillert, J.; Kappos, L.; Kieseier, B.; Killestein, J.; Malcus, C.; Comabella, M.; Pachner, A.; Schellekens, H.; Sellebjerg, F.; Selmaj, K.; Sorensen, P.S. Neutralising antibodies to interferon beta in multiple sclerosis : Expert panel report. J. Neurol., 2007, 254, 827-837.
63. Roach, E.S. Early multiple sclerosis: to treat or not to treat? Arch. Neurol., 2006, 63, 619.
64. Pittock, S.J.; Weinshenker, B.G.; Noseworthy, J.H.; Lucchinetti, C.F.; Keegan, M.; Wingerchuk, D.M.; Carter, J.; Shuster, E.; Rodriguez, M. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol., 2006, 63, 611-614.
65. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology, 1999, 53, 457-465.
66. Wiendl, H.; Hohlfeld, R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Bio- Drugs, 2002, 16, 183-200. (Pubitemid 34852318)
67. Zhang, J.; Hutton, G.; Zang, Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin. Ther., 2002, 24, 1998-2021. (Pubitemid 36051528)
68. Aharoni, R.; Kayhan, B.; Eilam, R.; Sela, M.; Arnon, R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA, 2003, 100, 14157-14162.
69. Azoulay, D.; Vachapova, V.; Shihman, B.; Miler, A.; Karni, A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol., 2005, 167, 215-218. (Pubitemid 41242305)
70. Filippi, M.; Rovaris, M.; Rocca, M.A.; Sormani, M.P.; Wolinsky, J.S.; Comi, G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology, 2001, 57, 731-733.
71. Khan, O.; Shen, Y.; Caon, C.; Bao, F.; Ching, W.; Reznar, M.; Buccheister, A.; Hu, J.; Latif, Z.; Tselis, A.; Lisak, R. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler., 2005, 11, 646-651. (Pubitemid 41685134)
72. Comi, G.; Filippi, M.; Wolinsky, J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imagingmeasured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol., 2001, 49, 290-297.
73. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L. W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995, 45, 1268-1276.
74. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L. W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B.; Vollmer, T.; Weiner, L.P.; Wolinsky, J.S. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1998, 50, 701-708.
75. Filippi, M.; Wolinsky, J.S.; Comi, G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol., 2006, 5, 213-220. (Pubitemid 43238344)
76. Schimrigk, S.; Brune, N.; Hellwig, K.; Lukas, C.; Bellenberg, B.; Rieks, M.; Hoffmann, V.; Pohlau, D.; Przuntek, H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an openlabel, baseline-controlled pilot study. Eur. J. Neurol., 2006, 13, 604-610. (Pubitemid 43873632)
77. Kappos, L.; Miller, D.; Dg., M.; Gold, R.; Havrdova, E.; Limmroth, V.; Polman, C.; Schmierer, K.; Yousry, T.; Yang, M.; Eraksoy, M.; Meluzinova, E.; Rektor, I.; O'Neill, G. Efficacy of a novel oral single- agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. J. Neurol., 2006, 253(Suppl), 27.
78. Rosen, H.; Goetzl, E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol., 2005, 5, 560-570.
79. Fujino, M.; Funeshima, N.; Kitazawa, Y.; Kimura, H.; Amemiya, H.; Suzuki, S.; Li, X.K. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther., 2003, 305, 70-77.
80. Webb, M.; Tham, C.S.; Lin, F.F.; Lariosa-Willingham, K.; Yu, N.; Hale, J.; Mandala, S.; Chun, J.; Rao, T.S. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental auto-immune encephalitis in SJL mice. J. Neuroimmunol., 2004, 153, 108-121.
81. Kappos, L.; Antel, J.; Comi, G.; Montalban, X.; O'connor, P.; Polman, C.H.; Haas, T.; Korn, A.A.; Karlsson, G.; Radue, E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 355, 1124-1140.
82. O'Connor, P.; Antel, J.; Comi, G. Oral FTY720 in relapsing MS: Results of the dose-blinded, active drug extension phase of a phase II study. Neurology, 2006, 66(Suppl), 123.
83. Ubogu, E.E.; Cossoy, M.B.; Ransohoff, R.M. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci., 2006, 27, 48-55.
84. Zipp, F.; Hartung, H.P.; Hillert, J.; Schimrigk, S.; Trebst, C.; Stangel, M.; Infante-Duarte, C.; Jakobs, P.; Wolf, C.; Sandbrink, R.; Pohl, C.; Filippi, M. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology, 2006, 67, 1880-1883. (Pubitemid 44900777)
85. Charo, I.F.; Ransohoff, R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006, 354, 610-621.
86. Greenwood, J.; Steinman, L.; Zamvil, S.S. Statin therapy and auto-immune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol., 2006, 6, 358-370.
87. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84.
88. Vollmer, T.; Key, L.; Durkalski, V.; Tyor, W.; Corboy, J.; Markovic- Plese, S.; Preiningerova, J.; Rizzo, M.; Singh, I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, 2004, 363, 1607-1608. (Pubitemid 38625664)
89. Tubridy, N.; Behan, P.O.; Capildeo, R.; Chaudhuri, A.; Forbes, R.; Hawkins, C.P.; Hughes, R.A.; Palace, J.; Sharrack, B.; Swingler, R.; Young, C.; Moseley, I.F.; Macmanus, D.G.; Donoghue, S.; Miller, D.H. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology, 1999, 53, 466-472.
90. Miller, D.H.; Khan, O.A.; Sheremata, W.A.; Blumhardt, L.D.; Rice, G.P.; Libonati, M.A.; Willmer-Hulme, A.J.; Dalton, C.M.; Miszkiel, K.A.; O'Connor, P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2003, 348, 15-23. (Pubitemid 36026342)
91. O'Connor, P.W.; Goodman, A.; Willmer-Hulme, A.J.; Libonati, M.A.; Metz, L.; Murray, R. S.; Sheremata, W.A.; Vollmer, T.L.; Stone, L.A. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology, 2004, 62, 2038-2043.
92. Polman, C.H.; O'connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354, 899-910.
93. Rudick, R.A.; Stuart, W.H.; Calabresi, P.A.; Confavreux, C.; Galetta, S.L.; Radue, E.W.; Lublin, F.D.; Weinstock-Guttman, B.; Wynn, D.R.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354, 911-923. (Pubitemid 43313658)
94. Hemmer, B.; Frohman, E.; Hartung, H.P.; Stuve, O. Central nervous system infections - a potential complication of systemic immunotherapy. Curr. Opin. Neurol., 2006, 19, 271-276.
95. Berger, T.; Weerth, S.; Kojima, K.; Linington, C.; Wekerle, H.; Lassmann, H. Experimental autoimmune encephalomyelitis: the antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab. Invest., 1997, 76, 355-364.
96. Moreau, T.; Thorpe, J.; Miller, D.; Moseley, I.; Hale, G.; Waldmann, H.; Clayton, D.; Wing, M.; Scolding, N.; Compston, A. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet, 1994, 344, 298-301.
97. Coles, A.J.; Wing, M.; Smith, S.; Coraddu, F.; Greer, S.; Taylor, C.; Weetman, A.; Hale, G.; Chatterjee, V.K.; Waldmann, H.; Compston, A. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet, 1999, 354, 1691-1695. (Pubitemid 29533060)
98. Coles, A. The CAMMS223 Study Group. Efficacy of alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223. Neurology 2007, 68(Suppl 1), A100.
99. Rastetter, W.; Molina, A.; White, C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med., 2004, 55, 477-503.
100. Cree, B.A.; Lamb, S.; Morgan, K.; Chen, A.; Waubant, E.; Genain, C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272.
101. Hauser, S.L.; Waubant, E.; Arnold, D.L.; Vollmer, T.; Antel, J.; Fox, R.J.; Bar-or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer- Gould, A.; Smith, C.H. B-cell depletion with rituximab in relapsing- remitting multiple sclerosis. N. Engl. J. Med., 2008, 358, 676-688.
102. Berger, J.R. Progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep., 2007, 7, 461-469.
103. Goebel, J.; Stevens, E.; Forrest, K.; Roszman, T.L. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol., 2000, 8, 153-159.
104. Tkaczuk, J.; Milford, E.; Yu, C.; Baksh, S.; Carpenter, C.; Burakoff, S.; Mckay, D. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab. Transplant. Proc., 2001, 33, 212-213.
105. Queen, C.; Schneider, W.P.; Selick, H.E.; Payne, P.W.; Landolfi, N.F.; Duncan, J.F.; Avdalovic, N.M.; Levitt, M.; Junghans, R.P.; Waldmann, T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 1989, 86, 10029-10033.
106. Bielekova, B.; Richert, N.; Howard, T.; Blevins, G.; Markovic- Plese, S.; Mccartin, J.; Frank, J.A.; Wurfel, J.; Ohayon, J.; Waldmann, T.A.; Mcfarland, H.F.; Martin, R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA, 2004, 101, 8705-8708.
107. Rose, J.W.; Watt, H.E.; White, A.T.; Carlson, N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol., 2004, 56, 864-867.
108. Rose, J.W.; Burns, J.B.; Bjorklund, J.; Klein, J.; Watt, H.E.; Carlson, N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology, 2007, 69, 785-789.
109. Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol., 2005, 23, 683-747.
110. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; Mcfarland, H.F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med., 2000, 6, 1167-1175.
111. Warren, K.G.; Catz, I.; Ferenczi, L.Z.; Krantz, M.J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol., 2006, 13, 887-895.
112. Bar-or, A.; Vollmer, T.; Antel, J.; Arnold, D.L.; Bodner, C.A.; Campagnolo, D.; Gianettoni, J.; Jalili, F.; Kachuck, N.; Lapierre, Y.; Niino, M.; Oger, J.; Price, M.; Rhodes, S.; Robinson, W.H.; Shi, F.D.; Utz, P.J.; Valone, F.; Weiner, L.; Steinman, L.; Garren, H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol., 2007, 64, 1407-1415.
113. Garren, H.; Krasulova, E.; Havrdova, E. Phase IIb trialof a MBP encoding DNA plasmid (BHT-3009) for the treatment of relapsing-remitting multiple sclerosis. Mult. Scler., 2007, 13, 17-18.
114. Vanderlugt, C.L.; Miller, S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol., 2002, 2, 85-95.
115. Bechtold, D.A.; Miller, S.J.; Dawson, A.C.; Sun, Y.; Kapoor, R.; Berry, D.; Smith, K.J. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol., 2006, 253, 1542-1551.
116. Black, J.A.; Liu, S.; Hains, B.C.; Saab, C.Y.; Waxman, S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain, 2006, 129, 3196-3208.
117. Ehrenreich, H.; Fischer, B.; Norra, C.; Schellenberger, F.; Stender, N.; Stiefel, M.; Siren, A. L.; Paulus, W.; Nave, K.A.; Gold, R.; Bartels, C. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain, 2007, 130, 2577-2588.
118. Gilgun-Sherki, Y.; Panet, H.; Melamed, E.; Offen, D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res., 2003, 989, 196-204.
119. Kalkers, N.F.; Barkhof, F.; Bergers, E.; Van Schijndel, R.; Polman, C.H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler., 2002, 8, 532-533.
120. Kapoor, R.; Davies, M.; Blaker, P.A.; Hall, S.M.; Smith, K.J. Blockers of sodium and calcium entry protect axons from nitric oxide- mediated degeneration. Ann. Neurol., 2003, 53, 174-180.
121. Li, W.; Maeda, Y.; Yuan, R.R.; Elkabes, S.; Cook, S.; Dowling, P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol., 2004, 56, 767-777.
122. Pryce, G.; Ahmed, Z.; Hankey, D.J.; Jackson, S.J.; Croxford, J.L.; Pocock, J.M.; Ledent, C.; Petzold, A.; Thompson, A.J.; Giovannoni, G.; Cuzner, M.L.; Baker, D. Cannabinoids inhibit neurode-generation in models of multiple sclerosis. Brain, 2003, 126, 2191-2202.
123. Smith, K. J. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol., 2007, 17, 230-242.
124. Kapoor, R. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design. Curr. Opin. Neurol., 2006, 19, 255-259.
125. Calabresi, P.A.; Fields, N.S.; Maloni, H.W.; Hanham, A.; Carlino, J.; Moore, J.; Levin, M. C.; Dhib-Jalbut, S.; Tranquill, L.R.; Austin, H.; Mcfarland, H.F.; Racke, M.K. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology, 1998, 51, 289-292.
126. Racke, M.K.; Dhib-Jalbut, S.; Cannella, B.; Albert, P.S.; Raine, C.S.; Mcfarlin, D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol., 1991, 146, 3012-3017.
127. Brines, M.; Cerami, A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci., 2005, 6, 484-494.
128. Ehrenreich, H.; Aust, C.; Krampe, H.; Jahn, H.; Jacob, S.; Herrmann, M.; Siren, A.L. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis., 2004, 19, 195-206.
129. Agnello, D.; Bigini, P.; Villa, P.; Mennini, T.; Cerami, A.; Brines, M.L.; Ghezzi, P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res., 2002, 952, 128-134.
130. Rodriguez, M.; Lennon, V.A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol., 1990, 27, 12-17.
131. Hommes, O.R.; Sorensen, P.S.; Fazekas, F.; Enriquez, M.M.; Koelmel, H.W.; Fernandez, O.; Pozzilli, C.; O'Connor, P. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet, 2004, 364, 1149-1156.
132. Noseworthy, J.H.; O'brien, P.C.; Petterson, T.M.; Weis, J.; Stevens, L.; Peterson, W.K.; Sneve, D.; Cross, S.A.; Leavitt, J.A.; Auger, R.G.; Weinshenker, B.G.; Dodick, D.W.; Wingerchuk, D.M.; Rodriguez, M. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology, 2001, 56, 1514-1522.
133. Noseworthy, J.H.; O'brien, P.C.; Weinshenker, B.G.; Weis, J.A.; Petterson, T.M.; Erickson, B.J.; Windebank, A.J.; Whisnant, J.P.; Stolp-Smith, K.A.; Harper, C.M., Jr.; Low, P.A.; Romme, L.J.; Johnson, M.; An, K.N.; Rodriguez, M. IV immunoglobulin does not reverse established weakness in MS.
134. Stangel, M.; Boegner, F.; Klatt, C.H.; Hofmeister, C.; Seyfert, S. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 2000, 68, 89-92.
135. Trebst, C.; Stangel, M. Promotion of remyelination by immuno-globulins: implications for the treatment of multiple sclerosis. Curr. Pharm. Des., 2006, 12, 241-249.
136. Warrington, A.E.; Asakura, K.; Bieber, A.J.; Ciric, B.; Van Keulen, V.; Kaveri, S.V.; Kyle, R.A.; Pease, L.R.; Rodriguez, M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA, 2000, 97, 6820-6825.
137. Pirko, I.; Ciric, B.; Gamez, J.; Bieber, A.J.; Warrington, A.E.; Johnson, A.J.; Hanson, D.P.; Pease, L.R.; Macura, S.I.; Rodriguez, M. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J., 2004, 18, 1577-1579.
138. Warrington, A.E.; Bieber, A.J.; Ciric, B.; Pease, L.R.; Van Keulen, V.; Rodriguez, M. A recombinant human IgM promotes myelin repair after a single, very low dose. J. Neurosci. Res., 2007, 85, 967-976.
139. Yong, V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci., 2005, 6, 931-944.
140. Yong, V.W.; Power, C.; Forsyth, P.; Edwards, D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci., 2001, 2, 502-511.
141. Correale, J.; Bassani Molinas Mde, L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J. Neuroimmunol., 2003, 140, 198-209.
142. Brundula, V.; Rewcastle, N.B.; Metz, L.M.; Bernard, C.C.; Yong, V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain, 2002, 125, 1297-1308.
143. Popovic, N.; Schubart, A.; Goetz, B.D.; Zhang, S.C.; Linington, C.; Duncan, I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol., 2002, 51, 215-223 .
144. Metz, L.M.; Zhang, Y.; Yeung, M.; Patry, D.G.; Bell, R.B.; Stoian, C.A.; Yong, V.W.; Patten, S.B.; Duquette, P.; Antel, J.P.; Mitchell, J.R. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol., 2004, 55, 756.
145. Zabad, R.K.; Metz, L.M.; Todoruk, T.R.; Zhang, Y.; Mitchell, J.R.; Yeung, M.; Patry, D. G.; Bell, R.B.; Yong, V.W. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult. Scler., 2007, 13, 517-526.
146. Lopachin, R.M.; Lehning, E.J. Mechanism of calcium entry during axon injury and degeneration. Toxicol. Appl. Pharmacol., 1997, 143, 233-244.
147. 2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol., 1991, 30, 375-380.
148. Bechtold, D.A.; Kapoor, R.; Smith, K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol., 2004, 55, 607-616.
149. Lo, A.C.; Saab, C.Y.; Black, J.A.; Waxman, S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol., 2003, 90, 3566-3571.